943 related articles for article (PubMed ID: 19171173)
1. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
[TBL] [Abstract][Full Text] [Related]
3. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.
Pavlenko M; Leder C; Roos AK; Levitsky V; Pisa P
Prostate; 2005 Jun; 64(1):50-9. PubMed ID: 15651071
[TBL] [Abstract][Full Text] [Related]
5. Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.
Mincheff M; Zoubak S; Altankova I; Tchakarov S; Pogribnyy P; Makogonenko Y; Botev C; Meryman HT
Cancer Gene Ther; 2005 Feb; 12(2):185-97. PubMed ID: 15375382
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.
Klyushnenkova EN; Link J; Oberle WT; Kodak J; Rich C; Vandenbark AA; Alexander RB
Clin Cancer Res; 2005 Apr; 11(8):2853-61. PubMed ID: 15837732
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
9. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
12. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.
Berlyn KA; Schultes B; Leveugle B; Noujaim AA; Alexander RB; Mann DL
Clin Immunol; 2001 Dec; 101(3):276-83. PubMed ID: 11726219
[TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
14. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
17. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
18. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
Kim JJ; Trivedi NN; Wilson DM; Mahalingam S; Morrison L; Tsai A; Chattergoon MA; Dang K; Patel M; Ahn L; Boyer JD; Chalian AA; Schoemaker H; Kieber-Emmons T; Agadjanyan MA; Weiner DB
Oncogene; 1998 Dec; 17(24):3125-35. PubMed ID: 9872328
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]